(PubMed) Tangney CC, Tang Y, Evans DA, Morris MC
The headline results, as released in the Eli Lilly investor communication and aligned with the study design paper by Giblin and colleagues published in Diabetes, Obesity and Metabolism in 2026, are unusually strong for a Phase 3 obesity trial: Retatrutide 12 mg: mean body-weight reduction of 28.7 percent, roughly 32.3 kg (about 71.2 lbs) from baseline
That mixture of like, Oh, look at me, I'm good at this stuff, clearly it's working, I have all these muscles to show for it. But also, you really know what youre talking about
One study found that ingesting a dose of 120-240 mg/day for one month significantly increased moisture in the participants skin and reduced the appearance of fine lines and wrinkles
And it has a synergistic effect, it appears, with chemotherapeutic drugs and radiation therapy